BTLA and neoplasm: BTLA+ Tregs may exhibit enhanced suppressive capacity, while BTLA+ B cells and DCs tend to exhibit impaired antigen presentation and costimulatory function, thereby limiting the priming and activation of new tumor-specific T cells [72].